Rituximab Combined with Steroid and Tacrolimus Treats Proliferative Glomerulonephritis with Monoclonal IgG Deposits : A Case Report and Review of the Literature
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
INTRODUCTION: Due to the confounding heterogeneity, the therapeutic strategy for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) remains to be defined.
CASE REPRESENTATION: We report a 38-year-old man with recurrent swelling of the eyelids and lower limbs, undergoing rituximab combined with steroid and tacrolimus treatment, who achieved an improved renal outcome. Underlying solid malignant tumours were excluded from the diagnosis.
DISCUSSION: We treated patients with rituximab along with steroids and tacrolimus. Improvements in proteinuria and renal function were observed. We also reviewed the current literature to assess the efficacy of rituximab in the treatment of PGNMID.
CONCLUSION: However, a larger pool of patients and a longer follow-up period are required to establish the role of rituximab and steroids in the treatment of PGNMID.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current medicinal chemistry - (2024) vom: 20. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Di [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 28.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0109298673272183240108093135 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36905363X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36905363X | ||
| 003 | DE-627 | ||
| 005 | 20240229171809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0109298673272183240108093135 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM36905363X | ||
| 035 | |a (NLM)38415439 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Di |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab Combined with Steroid and Tacrolimus Treats Proliferative Glomerulonephritis with Monoclonal IgG Deposits |b A Case Report and Review of the Literature |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a INTRODUCTION: Due to the confounding heterogeneity, the therapeutic strategy for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) remains to be defined | ||
| 520 | |a CASE REPRESENTATION: We report a 38-year-old man with recurrent swelling of the eyelids and lower limbs, undergoing rituximab combined with steroid and tacrolimus treatment, who achieved an improved renal outcome. Underlying solid malignant tumours were excluded from the diagnosis | ||
| 520 | |a DISCUSSION: We treated patients with rituximab along with steroids and tacrolimus. Improvements in proteinuria and renal function were observed. We also reviewed the current literature to assess the efficacy of rituximab in the treatment of PGNMID | ||
| 520 | |a CONCLUSION: However, a larger pool of patients and a longer follow-up period are required to establish the role of rituximab and steroids in the treatment of PGNMID | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Proliferative glomerulonephritis with monoclonal IgG deposits | |
| 650 | 4 | |a case report | |
| 650 | 4 | |a renal outcome | |
| 650 | 4 | |a rituximab | |
| 650 | 4 | |a steroids. | |
| 650 | 4 | |a tacrolimus | |
| 700 | 1 | |a Xia, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xuejing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Guochun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d 1997 |g (2024) vom: 20. Feb. |w (DE-627)NLM093833857 |x 1875-533X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:20 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0109298673272183240108093135 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 20 |c 02 | ||